RLMD
Relmada Therapeutics, Inc.4.5000
+0.1400+3.21%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
330.00MP/E (TTM)
-Basic EPS (TTM)
-1.78Dividend Yield
0%Recent Filings
8-K
Exec salary hikes, severance boosted
Relmada Therapeutics approved amended employment agreements for its executives on December 12, 2025, effective January 1, 2026, boosting CEO Traversa's salary to $827,176, COO Kelly's to $524,790, CFO Shenouda's to $586,940, and CAO Ence's to $576,440. Executives gain 12-month severance normally, 18 months post-change-in-control, plus accelerated equity vesting. Retention locked in. Risks hinge on release requirements.
8-K
NDV-01 92% response, FDA aligned
Relmada reported Q3 2025 net loss of $10.1M, down from $21.7M last year, with cash at $13.9M pre-financing. NDV-01 hit 92% complete response rate at 9 months in NMIBC Phase 2, securing FDA alignment for two Phase 3 paths starting H1 2026. Cash burn slashed. $100M offering closed November 5 funds ops into 2028.
10-Q
Q3 FY2025 results
Relmada narrowed Q3 losses to $10.1M from $21.7M y/y, with operating expenses dropping 55% to $10.3M (derived) as R&D fell 64% to $4.0M and G&A 47% to $6.3M, driven by esmethadone and psilocybin wind-downs. Nine-month net loss shrank to $37.5M from $61.3M y/y, or -$1.16 vs -$2.03 diluted EPS on 32.3M shares; anti-dilution kept basic=diluted. Cash burned $31.2M in operations yet ended at $1.4M plus $12.5M short-term investments; November offering added ~$94M net. In-licensed NDV-01 in March 2025 for $3.5M cash plus 3.0M shares and Sepranolone in February for $2.8M. Cash runway now covers 12 months. Nasdaq bid compliance regained September 2025. Clinical setbacks loom.
8-K
FDA backs NDV-01 Phase 3 paths
Relmada disclosed FDA feedback on November 4, 2025, greenlighting single-arm Phase 3 for BCG-unresponsive NMIBC (~100 patients) and randomized adjuvant trial for intermediate-risk (~266 patients), with no extra nonclinical studies needed. Phase 2 NDV-01 data showed 92% anytime complete response at 9 months among 25 patients, no Grade ≥3 AEs. Cash stood at ~$13.9M as of September 30. FDA may reject protocols.
8-K
NDV-01 Phase 2a data shines
Relmada Therapeutics updated its corporate presentation on September 17, 2025, highlighting NDV-01's positive Phase 2a data in non-muscle invasive bladder cancer, with 91% complete response rate and durable efficacy. NDV-01, a sustained-release Gem/Doce formulation, simplifies administration versus conventional therapy. Cash stands at $20.6 million; Phase 3 initiation targeted H1 2026. 9-month data due Q4 2025.
CADL
Candel Therapeutics, Inc.
5.74-0.03
CNBX
CNBX Pharmaceuticals Inc.
0.00+0.00
CORT
Corcept Therapeutics Incorporat
81.12-6.18
LRMR
Larimar Therapeutics, Inc.
3.74-0.18
NWBO
Northwest Biotherapeutics, Inc.
0.25+0.01
RADX
Radiopharm Theranostics Limited
5.99-4.64
RLFTF
RELIEF THERAPEUTICS HLDG AG
2.40+0.85
SMMT
Summit Therapeutics Inc.
17.23-0.15
TOVX
Theriva Biologics, Inc.
0.21+0.01
VNDA
Vanda Pharmaceuticals Inc.
6.65+0.02